HK1214528A1 - 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 - Google Patents

通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物

Info

Publication number
HK1214528A1
HK1214528A1 HK16102577.9A HK16102577A HK1214528A1 HK 1214528 A1 HK1214528 A1 HK 1214528A1 HK 16102577 A HK16102577 A HK 16102577A HK 1214528 A1 HK1214528 A1 HK 1214528A1
Authority
HK
Hong Kong
Prior art keywords
percutaneous
mucosal
interferon
subcutaneous
bone
Prior art date
Application number
HK16102577.9A
Other languages
English (en)
Inventor
魏光文
Original Assignee
Superlab Far East Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Superlab Far East Ltd filed Critical Superlab Far East Ltd
Publication of HK1214528A1 publication Critical patent/HK1214528A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
HK16102577.9A 2013-01-07 2016-03-07 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 HK1214528A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361749570P 2013-01-07 2013-01-07
US201361779711P 2013-03-13 2013-03-13
PCT/CN2014/070212 WO2014106492A2 (en) 2013-01-07 2014-01-07 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon

Publications (1)

Publication Number Publication Date
HK1214528A1 true HK1214528A1 (zh) 2016-07-29

Family

ID=51062515

Family Applications (4)

Application Number Title Priority Date Filing Date
HK16102577.9A HK1214528A1 (zh) 2013-01-07 2016-03-07 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
HK16104396.4A HK1216394A1 (zh) 2013-01-07 2016-04-18 用空間構象改變的重組干擾素治療腫瘤的方法
HK16105199.0A HK1217178A1 (zh) 2013-01-07 2016-05-06 用空間構象改變的重組干擾素治療腫瘤的方法
HK16105213.2A HK1217897A1 (zh) 2013-01-07 2016-05-06 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK16104396.4A HK1216394A1 (zh) 2013-01-07 2016-04-18 用空間構象改變的重組干擾素治療腫瘤的方法
HK16105199.0A HK1217178A1 (zh) 2013-01-07 2016-05-06 用空間構象改變的重組干擾素治療腫瘤的方法
HK16105213.2A HK1217897A1 (zh) 2013-01-07 2016-05-06 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物

Country Status (10)

Country Link
US (6) US20160022778A1 (zh)
EP (3) EP2941266B1 (zh)
JP (5) JP2016506413A (zh)
KR (4) KR20150139824A (zh)
CN (2) CN104994866A (zh)
AU (2) AU2014204386B2 (zh)
CA (2) CA2897312C (zh)
HK (4) HK1214528A1 (zh)
TW (3) TWI726291B (zh)
WO (2) WO2014106459A2 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726291B (zh) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
AU2016260845B2 (en) * 2015-05-12 2021-01-28 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
CN108721603B (zh) * 2017-04-14 2020-11-13 中国医学科学院基础医学研究所 干扰素α-1a在制备用于治疗癌症的药物中的用途
KR101880015B1 (ko) * 2017-12-08 2018-07-19 아주대학교산학협력단 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물
US20220025349A1 (en) * 2018-11-27 2022-01-27 The Children's Hospital Of Philadelphia Compositions and methods for treating cancer
US20220251605A1 (en) * 2019-06-14 2022-08-11 The Brigham And Women's Hospital, Inc. Membrane attack complexes and uses thereof
AU2022210179A1 (en) * 2021-01-21 2023-09-07 Biosteed Gene Transformation Tech. Co., Ltd. Interferon-based cancer treatment method, and pharmaceutical combination
US11759434B2 (en) * 2022-02-03 2023-09-19 Sytheon Limited Methods and compositions for treating melanoma and non-melanoma skin cancers
CN114533706B (zh) * 2022-02-15 2022-10-14 深圳市利云德生物技术有限公司 一种用于防治呼吸道疾病的雾化吸入制剂及其应用
WO2024076973A1 (en) * 2022-10-04 2024-04-11 Brown University Compositions and methods of delivering large proteins
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2005169A (en) * 1932-08-27 1935-06-18 Rowe Andrew Reed Casting metal ingots
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4681930A (en) 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US4846782A (en) * 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
DE69233690T2 (de) 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Abgabevorrichtung für nebelförmige Medikamente
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
PL172758B1 (pl) 1992-10-19 1997-11-28 Dura Pharma Inc Inhalator do proszków suchych PL PL PL PL PL PL PL
DK0680451T3 (da) 1993-01-19 1999-07-19 Glaxo Group Ltd Aerosoldispenser samt fremgangsmåde ved dens fremstilling
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
DE69431071T2 (de) * 1993-12-29 2003-03-20 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US6579695B1 (en) 1995-10-13 2003-06-17 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
JP2000503565A (ja) 1996-01-03 2000-03-28 グラクソ、グループ、リミテッド 吸入装置
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
CN1062565C (zh) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 重组人α型复合干扰素及其制备方法和用途
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
JP3983985B2 (ja) 2000-03-22 2007-09-26 株式会社東芝 ＭｘＡタンパク質の多型遺伝子およびその使用
EP2292652A2 (en) 2000-11-03 2011-03-09 Pestka Biomedical Laboratories, Inc. Interferons uses and compositions related thereto
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
CN1375502A (zh) 2001-10-25 2002-10-23 南京药科大学 聚乙二醇修饰重组人干扰素
KR100941909B1 (ko) 2002-02-19 2010-02-16 히사미쓰 세이야꾸 가부시키가이샤 경피흡수형 부착제
WO2004091571A2 (en) 2003-04-08 2004-10-28 New Jersey Institute Of Technology (Njit) Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
SI2325202T1 (sl) * 2003-08-28 2015-02-27 Superlab Far East Limited Uporabe interferonov s spremenjeno prostorsko strukturo
MY141751A (en) * 2003-08-28 2010-06-30 Sichuan Biotechnology Res Ct Recombinant super-compound interferon
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
CN1910195A (zh) * 2003-08-28 2007-02-07 辉阳科技美国公司 通过空间构象调节蛋白质功能
KR20060130009A (ko) * 2003-08-28 2006-12-18 휴이양테크 (유에스에이), 인크. 변경된 공간 구조를 갖는 인터페론의 용도
FR2862541B1 (fr) * 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2006088473A2 (en) * 2004-04-23 2006-08-24 Panduranga Rao Koritala Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
CN1740197B (zh) 2004-08-26 2010-05-12 辉阳科技美国公司 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
CA2597317C (en) * 2005-03-09 2018-01-02 Guangwen Wei Uses of recombinant super-compound interferons
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2008541769A (ja) 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用
US8071125B2 (en) 2005-12-09 2011-12-06 Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. Transdermal patch containing isosorbide dinitrate and bisoprolol
MX2009001226A (es) 2006-08-04 2009-03-20 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
US8095213B1 (en) 2007-05-31 2012-01-10 Purdue Pharma L.P. Transdermal patch
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
CN102378626B (zh) * 2009-03-30 2014-05-14 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
EP2239580B1 (en) 2009-04-09 2013-03-27 Lga Biotecnologie Srl Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
BR112013007327A2 (pt) 2010-09-27 2017-07-04 Zestagen S A anticorpo quimérico isolado, polipeptídeo isolado, vetor de expressão, célula, métodos para produzir o anticorpo quimérico, para reduzir o crescimento e/ou a capacidade de invasão de uma célula neoplástica, para tratar um indivíduo que tem uma neoplasia, e para tratar ou prevenir a progressão de tumor ou metástase, composição farmacêutica, e, kit
US9107887B2 (en) * 2011-03-10 2015-08-18 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
US20130184437A9 (en) 2011-06-08 2013-07-18 Guangwen Wei Design and use of new recombinant interferons with altered spatial configuration and three-dimensional structure
US10016484B2 (en) 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer
US20130273527A1 (en) * 2012-04-13 2013-10-17 Superlab Far East Limited Method for inducing cell senescence by recombinant interferon with altered spatial configuration
JP2015524397A (ja) * 2012-07-20 2015-08-24 ラトローブ ユニヴァーシティ 診断及び処置の方法
TWI726291B (zh) * 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US10677782B2 (en) 2013-11-13 2020-06-09 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof

Also Published As

Publication number Publication date
HK1217178A1 (zh) 2016-12-30
AU2014204386A1 (en) 2015-08-27
CA2897312C (en) 2022-11-01
EP2941266B1 (en) 2022-05-25
US20180326012A1 (en) 2018-11-15
TW201427682A (zh) 2014-07-16
EP2941266A4 (en) 2016-09-07
EP2941264A4 (en) 2016-08-31
US20220339255A1 (en) 2022-10-27
TW201427681A (zh) 2014-07-16
KR20150103284A (ko) 2015-09-09
US20150352188A1 (en) 2015-12-10
US20160022778A1 (en) 2016-01-28
KR20210069127A (ko) 2021-06-10
HK1216394A1 (zh) 2016-11-11
CA2897312A1 (en) 2014-07-10
JP2022031331A (ja) 2022-02-18
WO2014106459A8 (en) 2015-08-06
WO2014106492A2 (en) 2014-07-10
CN104902917A (zh) 2015-09-09
EP2941264B1 (en) 2021-03-10
JP2020023547A (ja) 2020-02-13
AU2014204368B2 (en) 2018-08-23
HK1217897A1 (zh) 2017-01-27
WO2014106459A3 (en) 2014-09-04
JP2016506413A (ja) 2016-03-03
TWI718086B (zh) 2021-02-11
US10874716B2 (en) 2020-12-29
TWI726291B (zh) 2021-05-01
WO2014106492A3 (en) 2014-08-28
WO2014106459A2 (en) 2014-07-10
US20210260164A1 (en) 2021-08-26
KR20210077005A (ko) 2021-06-24
EP3895725A2 (en) 2021-10-20
TW201940189A (zh) 2019-10-16
EP2941266A2 (en) 2015-11-11
CN104994866A (zh) 2015-10-21
EP2941264A2 (en) 2015-11-11
US20180344811A1 (en) 2018-12-06
CA2897335A1 (en) 2014-07-10
JP2016508987A (ja) 2016-03-24
AU2014204386B2 (en) 2018-07-26
KR20150139824A (ko) 2015-12-14
JP2020105223A (ja) 2020-07-09
US12109250B2 (en) 2024-10-08
EP3895725A3 (en) 2021-12-01
AU2014204368A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
HK1217897A1 (zh) 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
IL276428A (en) A preparation and vaccine for the treatment of lung cancer
IL273090B (en) Methods and preparations for the treatment of cancer
HK1217289A1 (zh) 使用細菌治療癌症的組合物和方法
EP3071209A4 (en) Use of sting agonist as cancer treatment
HK1215017A1 (zh) 治療帕金森疾病的新型高穿透力藥物和醫藥組合物
EP2943565A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTRATION OF IMMUNE CELLS FOR TREATING TUMOR CELLS THAT ARE NOT RESTRICTED OR UNREQUIRED AND A TUMOR RECIPIENT
MY188139A (en) Sodium channel modulators for the treatment of pain
SG10201910792WA (en) Vascularized tissue, skin or mucosa equivalent
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
WO2014153221A3 (en) Acth for treatment of acute respiratory distress syndrome
HK1210788A1 (zh) 用於治療肝細胞癌的治療性生物製品
EP3071214A4 (en) Salacia compositions, methods of treatment by their administration, and methods of their preparation
MD4629B1 (ro) Metode de tratament a fibrozei şi cancerului
EP2958591A4 (en) METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF CANCER
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
IL245998A0 (en) Pharmaceutical preparations and a method for the treatment of metastatic cancer and its prevention
PL3035955T3 (pl) Kompozycja i szczepionka do leczenia raka płuca
PL3041459T3 (pl) Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry
GB2553684B (en) Ethynylxanthines, preparation and use for cancer treatment